Balyasny Asset Management
KYNB

Balyasny Asset Management’s Kyntra Bio KYNB Stock Holding History

Balyasny Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-776
Closed -$17.3K – 2873
2024
Q2 		$17.3K Buy
+776
New +$24K ﹤0.01% 2476
2023
Q4 		– Sell
-3,858
Closed -$83.2K – 2609
2023
Q3 		$83.2K Sell
3,858
-11,177
-74% -$439K ﹤0.01% 2137
2023
Q2 		$1.01M Buy
15,035
+13,913
+1,240% +$5.75M ﹤0.01% 1614
2023
Q1 		$523K Buy
+1,122
New +$594K ﹤0.01% 1939
2022
Q1 		– Sell
-448
Closed -$158K – 2586
2021
Q4 		$158K Buy
+448
New +$139K ﹤0.01% 1897
2016
Q1 		– Sell
-591
Closed -$450K – 1349
2015
Q4 		$450K Buy
+591
New +$392K ﹤0.01% 861
2015
Q1 		– Sell
-763
Closed -$521K – 980
2014
Q4 		$521K Buy
+763
New +$491K ﹤0.01% 613

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Balyasny Asset Management's KYNB Position: Q3 2024 in Review

Balyasny Asset Management sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 776 shares — an estimated $17.3K sold.

Balyasny Asset Management first reported a position in KYNB in Q4 2014 and held it in 7 quarters. The position peaked at $1.01M in Q2 2023. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • Balyasny Asset Management reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 776 Kyntra Bio shares in Q3 2024, an estimated $17.3K.
  • Balyasny Asset Management first reported a position in Kyntra Bio in Q4 2014 and held it in 7 quarters.
  • Balyasny Asset Management's Kyntra Bio position peaked at $1.01M in Q2 2023.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.